p16-null/p53-proficient A549 TIS cancer cells are resistant to BCL2- and MCL-1-specific inhibitors, but show variable responses to the BCL-XL-targeting BH3 mimetics ABT-263/navitoclax and A1331852. This evidence concerns the gene BCL2L1 and cancer.